Atrasentan: Clinical Trials

25 trials of Atrasentan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 active not recruiting, 2 not yet recruiting, 2 recruiting. 12 Phase 2, 10 Phase 3, 1 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 212Completed 10, Active not recruiting 1, Terminated 1
Phase 310Completed 6, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 11Completed 1
Phase 41Not yet recruiting 1

Follow Atrasentan: new trials by email Literature Review of Atrasentan trials Research Report on Atrasentan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN)
Phase 3Not yet recruitingNovartis Pharmaceuticals3402026-12-012026-09-30
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Phase 4Not yet recruitingUniversity of Illinois at Chicago202026-09-292026-09-21
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Drug: Atrasentan - Berger Disease, Bergers Disease
Phase 3RecruitingNovartis Pharmaceuticals282026-08-062026-11-06
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
No intervention, Other treatment, Iptacopan - Immunoglobulin A Nephropathy
RecruitingNovartis Pharmaceuticals3002025-03-042025-06-17
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy
Phase 2CompletedNovartis Pharmaceuticals542023-07-202026-07-20
Atrasentan in Patients With Proteinuric Glomerular Diseases
Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis
Phase 2Active not recruitingNovartis Pharmaceuticals1032021-03-152026-06-01
Atrasentan in Patients With IgA Nephropathy
Atrasentan, Placebo, Zigakibart - IgA Nephropathy, Immunoglobulin A Nephropathy
Phase 3Active not recruitingNovartis Pharmaceuticals4042020-12-112026-06-04
Atrasentan Spermatogenesis and Testicular Function
Atrasentan - Nephropathy, Diabetes
Phase 2CompletedAbbVie202015-04-062019-05-07
Study Of Diabetic Nephropathy With Atrasentan
Atrasentan, Placebo - Diabetic Nephropathy
Phase 3TerminatedAbbVie51072013-05-172019-04-24
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)482011-08-012013-10-25
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Atrasentan low dose group, Atrasentan high dose group, Atrasentan placebo group - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)582011-08-012017-08-29
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)1492011-04-012013-08-28
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)922009-06-012018-06-06
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
atrasentan hydrochloride, docetaxel, prednisone - Metastatic Cancer, Prostate Cancer
Phase 3CompletedSWOG Cancer Research Network10382006-08-012021-10-27
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
atrasentan hydrochloride - Kidney Cancer
Phase 2CompletedEastern Cooperative Oncology Group1802003-07-142023-06-22
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
atrasentan hydrochloride, doxil - Fallopian Tube Cancer, Ovarian Cancer
Phase 2TerminatedVanderbilt-Ingram Cancer Center152003-05-012012-05-23
Atrasentan in Treating Patients With Prostate Cancer
atrasentan hydrochloride - Prostate Cancer
Phase 3CompletedAbbott2002-09-012011-02-21
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
atrasentan hydrochloride - Brain and Central Nervous System Tumors
Phase 1CompletedNational Cancer Institute (NCI)2002-06-012009-01-13
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Atrasentan - Prostatic Neoplasms
Phase 2CompletedAbbott2002002-05-012006-08-15
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Atrasentan, Zoledronic Acid (Zometa) - Prostate Cancer, Adenocarcinoma of the Prostate
Phase 2CompletedMassachusetts General Hospital442001-12-012010-05-10

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Glomerulonephritis, IGA (8)  ·  Diabetic Nephropathies (7)  ·  Prostatic Neoplasms (7)  ·  Renal Insufficiency, Chronic (7)  ·  Kidney Diseases (5)  ·  Proteinuria (4)  ·  Urologic Diseases (4)  ·  Glomerulonephritis (3)  ·  Diabetes Mellitus (2)  ·  Adenocarcinoma (1)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Carcinoma, Renal Cell (1)  ·  Central Nervous System Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (7)  ·  Abbott (5)  ·  AbbVie (prior sponsor, Abbott) (4)  ·  AbbVie (2)  ·  Eastern Cooperative Oncology Group (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  National Cancer Institute (NCI) (1)  ·  SWOG Cancer Research Network (1)  ·  University of Illinois at Chicago (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (21)  ·  Spain (7)  ·  Canada (6)  ·  Australia (5)  ·  France (5)  ·  Italy (5)  ·  United Kingdom (5)  ·  Germany (4)  ·  South Korea (4)  ·  Japan (3)  ·  Netherlands (3)  ·  New Zealand (3)  ·  Poland (3)  ·  Taiwan (3)  ·  Austria (2)

Top investigators

Blai Coll, MD (2)  ·  Darryl Sleep, M.D. (2)  ·  Amir Lerman, M.D. (1)  ·  Anand Srivastava, MD, MPH (1)  ·  David I. Quinn, MD (1)  ·  Dennis Andress (1)  ·  Gary Gordon, M.D. (1)  ·  Gary Gordon, MD (1)  ·  Gary Gordon, MD, PhD (1)  ·  Maha Hadi A. Hussain, MD (1)  ·  Mark Garzotto, MD (1)  ·  Marta Crispens, MD (1)  ·  Matthew Smith, MD, PhD (1)

Results publications

PMID 28756065, PMID 37716952, PMID 41442197, PMID 18477765, PMID 20733096, PMID 23871417, PMID 24565955, PMID 24616308, PMID 24722445, PMID 26153128, PMID 30995972, PMID 33270906, PMID 33338269, PMID 34853062, PMID 35772861, PMID 37254256, PMID 37657768, PMID 37872654, PMID 38059359, PMID 38299639, PMID 39460694, PMID 39661119, PMID 39899371, PMID 40526444, PMID 40938675, PMID 41904616, PMID 42242268

NIH funding

2016 (1), 2023 (1), U10CA032102 (1)